A detailed history of Met Life Investment Management, LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 45,200 shares of AVIR stock, worth $147,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,200
Previous 45,200 -0.0%
Holding current value
$147,804
Previous $149,000 1.34%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.31 - $4.04 $24,742 - $30,199
7,475 Added 19.81%
45,200 $149,000
Q1 2024

May 14, 2024

BUY
$3.09 - $4.56 $116,570 - $172,025
37,725 New
37,725 $152,000
Q2 2023

Apr 29, 2024

BUY
$3.21 - $5.06 $151,621 - $239,004
47,234 New
47,234 $176,000
Q2 2023

Aug 10, 2023

BUY
$3.21 - $5.06 $151,621 - $239,004
47,234 New
47,234 $176,000
Q1 2023

May 09, 2024

BUY
$3.0 - $4.97 $141,702 - $234,752
47,234 New
47,234 $158 Million
Q4 2022

Jun 14, 2023

BUY
$4.35 - $6.17 $205,467 - $291,433
47,234 New
47,234 $227,000
Q3 2022

May 10, 2024

BUY
$5.49 - $8.79 $44,842 - $71,796
8,168 Added 20.91%
47,234 $268,000
Q3 2022

Jun 14, 2023

BUY
$5.49 - $8.79 $259,314 - $415,186
47,234 New
47,234 $268,000
Q3 2022

Mar 22, 2023

BUY
$5.49 - $8.79 $44,842 - $71,796
8,168 Added 20.91%
47,234 $268,000
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $44,842 - $71,796
8,168 Added 20.91%
47,234 $269,000
Q2 2022

Jun 20, 2023

BUY
$5.33 - $8.18 $208,221 - $319,559
39,066 New
39,066 $277,000
Q1 2022

May 10, 2024

BUY
$5.5 - $9.19 $214,863 - $359,016
39,066 New
39,066 $282,000
Q1 2022

Jun 20, 2023

BUY
$5.5 - $9.19 $214,863 - $359,016
39,066 New
39,066 $282,000
Q1 2022

Mar 22, 2023

BUY
$5.5 - $9.19 $79,299 - $132,501
14,418 Added 58.5%
39,066 $282,000
Q1 2022

May 12, 2022

BUY
$5.5 - $9.19 $79,299 - $132,501
14,418 Added 58.5%
39,066 $282,000
Q4 2021

Jun 21, 2023

BUY
$7.67 - $44.59 $189,050 - $1.1 Million
24,648 New
24,648 $220,000
Q3 2021

Jun 21, 2023

BUY
$21.33 - $35.06 $525,741 - $864,158
24,648 New
24,648 $864,000
Q2 2021

May 17, 2024

BUY
$19.22 - $59.08 $367,082 - $1.13 Million
19,099 Added 344.19%
24,648 $529,000
Q2 2021

Mar 22, 2023

BUY
$19.22 - $59.08 $367,082 - $1.13 Million
19,099 Added 344.19%
24,648 $529,000
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $367,082 - $1.13 Million
19,099 Added 344.19%
24,648 $529,000
Q1 2021

May 17, 2024

SELL
$41.42 - $88.44 $1.33 Million - $2.85 Million
-32,176 Reduced 85.29%
5,549 $342,000
Q1 2021

Jun 26, 2023

BUY
$41.42 - $88.44 $229,839 - $490,753
5,549 New
5,549 $343 Million
Q1 2021

Mar 22, 2023

SELL
$41.42 - $88.44 $57,449 - $122,666
-1,387 Reduced 20.0%
5,549 $342,000
Q1 2021

May 14, 2021

SELL
$41.42 - $88.44 $57,449 - $122,666
-1,387 Reduced 20.0%
5,549 $343,000
Q4 2020

May 24, 2024

SELL
$26.36 - $41.78 $811,598 - $1.29 Million
-30,789 Reduced 81.61%
6,936 $289,000
Q4 2020

Jun 22, 2023

BUY
$26.36 - $41.78 $182,832 - $289,786
6,936 New
6,936 $289,000
Q4 2020

Mar 22, 2023

SELL
$26.36 - $41.78 $1.06 Million - $1.68 Million
-40,298 Reduced 85.32%
6,936 $289,000
Q4 2020

Feb 16, 2021

BUY
$26.36 - $41.78 $182,832 - $289,786
6,936 New
6,936 $290,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $272M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.